Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short term Debt (2017 - 2025)

United Therapeutics' Short term Debt history spans 6 years, with the latest figure at $200.0 million for Q1 2025.

  • On a quarterly basis, Short term Debt fell 50.0% to $200.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $200.0 million, a 50.0% decrease, with the full-year FY2024 number at $300.0 million, down 25.0% from a year prior.
  • Short term Debt hit $200.0 million in Q1 2025 for United Therapeutics, down from $300.0 million in the prior quarter.
  • Over the last five years, Short term Debt for UTHR hit a ceiling of $400.0 million in Q4 2023 and a floor of $200.0 million in Q1 2025.
  • Historically, Short term Debt has averaged $342.9 million across 3 years, with a median of $400.0 million in 2023.
  • Biggest five-year swings in Short term Debt: soared 33.33% in 2024 and later crashed 50.0% in 2025.
  • Tracing UTHR's Short term Debt over 3 years: stood at $400.0 million in 2023, then fell by 25.0% to $300.0 million in 2024, then tumbled by 33.33% to $200.0 million in 2025.
  • Business Quant data shows Short term Debt for UTHR at $200.0 million in Q1 2025, $300.0 million in Q4 2024, and $400.0 million in Q3 2024.